Literature DB >> 16700545

Surface plasmon resonance analysis of antifungal azoles binding to CYP3A4 with kinetic resolution of multiple binding orientations.

Josh T Pearson1, John J Hill, Jennifer Swank, Nina Isoherranen, Kent L Kunze, William M Atkins.   

Abstract

The heme-containing cytochrome P450s (CYPs) are a major enzymatic determinant of drug clearance and drug-drug interactions. The CYP3A4 isoform is inhibited by antifungal imidazoles or triazoles, which form low-spin heme iron complexes via formation of a nitrogen-ferric iron coordinate bond. However, CYP3A4 also slowly oxidizes the antifungal itraconazole (ITZ) at a site that is approximately 25 A from the triazole nitrogens, suggesting that large antifungal azoles can adopt multiple orientations within the CYP3A4 active site. Here, we report a surface plasmon resonance (SPR) analysis with kinetic resolution of two binding modes of ITZ, and the related drug ketoconazole (KTZ). SPR reveals a very slow off-rate for one binding orientation. Multiphasic binding kinetics are observed, and one of the two binding components resolved by curve fitting exhibits "equilibrium overshoot". Preloading of CYP3A4 with the heme ligand imidazole abolishes this component of the antifungal azole binding trajectories, and it eliminates the conspicuously slow off-rate. The fractional populations of CYP3A4 complexes corresponding to different drug orientations can be manipulated by altering the duration of the pulse of drug exposure. UV-vis difference absorbance titrations yield low-spin spectra and K(D) values that are consistent with the high-affinity complex resolved by SPR. These results demonstrate that ITZ and KTZ bind in multiple orientations, including a catalytically productive mode and a slowly dissociating inhibitory mode. Most importantly, they provide the first example of a SPR-based method for the kinetic characterization of binding of a drug to any human CYP, including mechanistic insight not available from other methods.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16700545      PMCID: PMC2701698          DOI: 10.1021/bi0600042

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  53 in total

Review 1.  Advances in surface plasmon resonance biosensor analysis.

Authors:  R L Rich; D G Myszka
Journal:  Curr Opin Biotechnol       Date:  2000-02       Impact factor: 9.740

2.  Analysis of homotropic and heterotropic cooperativity of diazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling.

Authors:  You Ai He; Fabienne Roussel; James R Halpert
Journal:  Arch Biochem Biophys       Date:  2003-01-01       Impact factor: 4.013

Review 3.  A passion for P450s (rememberances of the early history of research on cytochrome P450).

Authors:  Ronald W Estabrook
Journal:  Drug Metab Dispos       Date:  2003-12       Impact factor: 3.922

Review 4.  Atypical enzyme kinetics: their effect on in vitro-in vivo pharmacokinetic predictions and drug interactions.

Authors:  Timothy S Tracy
Journal:  Curr Drug Metab       Date:  2003-10       Impact factor: 3.731

5.  Crystallographic studies on the complex behavior of nicotine binding to P450cam (CYP101).

Authors:  Michael Strickler; Barry M Goldstein; Kathleen Maxfield; Laura Shireman; Gyungyoun Kim; Donald S Matteson; Jeffrey P Jones
Journal:  Biochemistry       Date:  2003-10-21       Impact factor: 3.162

6.  Crystal structure of human cytochrome P450 2C9 with bound warfarin.

Authors:  Pamela A Williams; Jose Cosme; Alison Ward; Hayley C Angove; Dijana Matak Vinković; Harren Jhoti
Journal:  Nature       Date:  2003-07-13       Impact factor: 49.962

7.  An open conformation of mammalian cytochrome P450 2B4 at 1.6-A resolution.

Authors:  Emily E Scott; You Ai He; Michael R Wester; Mark A White; Christopher C Chin; James R Halpert; Eric F Johnson; C David Stout
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-16       Impact factor: 11.205

8.  Pyrene.pyrene complexes at the active site of cytochrome P450 3A4: evidence for a multiple substrate binding site.

Authors:  Michael J Dabrowski; Michael L Schrag; Larry C Wienkers; William M Atkins
Journal:  J Am Chem Soc       Date:  2002-10-09       Impact factor: 15.419

9.  Multisite kinetic analysis of interactions between prototypical CYP3A4 subgroup substrates: midazolam, testosterone, and nifedipine.

Authors:  Aleksandra Galetin; Stephen E Clarke; J Brian Houston
Journal:  Drug Metab Dispos       Date:  2003-09       Impact factor: 3.922

10.  Structure of a substrate complex of mammalian cytochrome P450 2C5 at 2.3 A resolution: evidence for multiple substrate binding modes.

Authors:  Michael R Wester; Eric F Johnson; Cristina Marques-Soares; Patrick M Dansette; Daniel Mansuy; C David Stout
Journal:  Biochemistry       Date:  2003-06-03       Impact factor: 3.162

View more
  31 in total

1.  The effects of type II binding on metabolic stability and binding affinity in cytochrome P450 CYP3A4.

Authors:  Chi-Chi Peng; Josh T Pearson; Dan A Rock; Carolyn A Joswig-Jones; Jeffrey P Jones
Journal:  Arch Biochem Biophys       Date:  2010-03-25       Impact factor: 4.013

Review 2.  Substrate binding to cytochromes P450.

Authors:  Emre M Isin; F Peter Guengerich
Journal:  Anal Bioanal Chem       Date:  2008-07-13       Impact factor: 4.142

3.  Role of subunit interactions in P450 oligomers in the loss of homotropic cooperativity in the cytochrome P450 3A4 mutant L211F/D214E/F304W.

Authors:  Harshica Fernando; Dmitri R Davydov; Christopher C Chin; James R Halpert
Journal:  Arch Biochem Biophys       Date:  2007-01-12       Impact factor: 4.013

Review 4.  Role of biotransformation studies in minimizing metabolism-related liabilities in drug discovery.

Authors:  Yue-Zhong Shu; Benjamin M Johnson; Tian J Yang
Journal:  AAPS J       Date:  2008-03-13       Impact factor: 4.009

Review 5.  Use of chemical auxiliaries to control p450 enzymes for predictable oxidations at unactivated C-h bonds of substrates.

Authors:  Karine Auclair; Vanja Polic
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

6.  The effects of nitrogen-heme-iron coordination on substrate affinities for cytochrome P450 2E1.

Authors:  Jeffrey P Jones; Carolyn A Joswig-Jones; Michelle Hebner; Yuzhuo Chu; Dennis R Koop
Journal:  Chem Biol Interact       Date:  2011-05-10       Impact factor: 5.192

Review 7.  Current Approaches for Investigating and Predicting Cytochrome P450 3A4-Ligand Interactions.

Authors:  Irina F Sevrioukova; Thomas L Poulos
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

8.  2-aminoimidazole amino acids as inhibitors of the binuclear manganese metalloenzyme human arginase I.

Authors:  Monica Ilies; Luigi Di Costanzo; Michelle L North; Jeremy A Scott; David W Christianson
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

9.  Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs.

Authors:  Jyothi C Talakad; Santosh Kumar; James R Halpert
Journal:  Drug Metab Dispos       Date:  2008-12-12       Impact factor: 3.922

10.  Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.

Authors:  I E Templeton; K E Thummel; E D Kharasch; K L Kunze; C Hoffer; W L Nelson; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2007-05-09       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.